John Hood
Director Ejecutivo en Actavalon, Inc. .
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Ned Israelsen | M | - |
Actavalon, Inc.
 Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA. | - |
| Michael S. Egan | M | 83 |
Actavalon, Inc.
Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA. | - |
| G. Wesley Hatfield | M | - |
Actavalon, Inc.
Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA. | - |
| Miguel A. de los Ríos | M | 49 |
Endeavor BioMedicines, Inc
 Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | - |
| Matthew Jacobson | M | - |
Nine Square Therapeutics, Inc.
 Nine Square Therapeutics, Inc. BiotechnologyHealth Technology Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY. | 4 años |
| Seth Harrison | M | 63 |
Nine Square Therapeutics, Inc.
Nine Square Therapeutics, Inc. BiotechnologyHealth Technology Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY. | - |
| Bernard Davitian | M | 63 |
Endeavor BioMedicines, Inc
Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | - |
| Michael Ehlers | M | - |
Nine Square Therapeutics, Inc.
Nine Square Therapeutics, Inc. BiotechnologyHealth Technology Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY. | - |
| Teague Egan | M | 35 |
Actavalon, Inc.
Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA. | - |
| Van E. Haynie | M | - |
Actavalon, Inc.
Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA. | - |
| Robert Paul | M | 56 |
Nine Square Therapeutics, Inc.
Nine Square Therapeutics, Inc. BiotechnologyHealth Technology Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY. | 2 años |
| Michael Ehlers | M | - |
Nine Square Therapeutics, Inc.
Nine Square Therapeutics, Inc. BiotechnologyHealth Technology Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY. | - |
| Matthew Jacobson | M | - |
Nine Square Therapeutics, Inc.
Nine Square Therapeutics, Inc. BiotechnologyHealth Technology Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Charles McDermott | M | 52 |
Impact Biomedicines, Inc.
 Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | 1 años |
| Jonathan Edwards | M | 40 |
Impact Biomedicines, Inc.
Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | 1 años |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 15 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- John Hood
- Red Personal
